Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SRIDHAR BEERAM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1275626970
CMS profile
193459
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$19,307.07

412 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $10,955.72 64
E.R. Squibb & Sons, L.L.C. $2,780.98 28
AstraZeneca Pharmaceuticals LP $800.28 23
Amgen Inc. $488.98 19
Genentech USA, Inc. $437.29 34
Novartis Pharmaceuticals Corporation $351.60 27
GENZYME CORPORATION $291.79 18
Incyte Corporation $279.36 13
Janssen Biotech, Inc. $251.66 14
AbbVie, Inc. $229.57 8
Merck Sharp & Dohme Corporation $213.78 18
Rigel Pharmaceuticals, Inc. $201.71 11
Celgene Corporation $168.22 10
EISAI INC. $155.54 14
Lilly USA, LLC $139.55 20
Astellas Pharma US Inc $134.73 12
Takeda Pharmaceuticals U.S.A., Inc. $134.19 4
Bayer HealthCare Pharmaceuticals Inc. $124.48 8
Exelixis Inc. $110.48 9
Janssen Pharmaceuticals, Inc $106.00 6
Boehringer Ingelheim Pharmaceuticals, Inc. $95.51 7
Verastem, Inc. $88.87 1
Clovis Oncology, Inc. $75.99 1
Seattle Genetics, Inc. $69.37 5
Ipsen Biopharmaceuticals, Inc $66.30 3
Puma Biotechnology, Inc. $60.10 4
Regeneron Healthcare Solutions, Inc. $50.40 3
TerSera Therapeutics LLC $49.16 3
TOLMAR Pharmaceuticals, Inc. $45.47 3
Alexion Pharmaceuticals, Inc. $39.55 3
TESARO, Inc. $37.80 2
Medtronic USA, Inc. $29.84 2
Lexicon Pharmaceuticals, Inc. $28.92 1
JAZZ PHARMACEUTICALS INC. $26.21 2
Foundation Medicine, Inc. $24.94 1
Teva Pharmaceuticals USA, Inc. $24.28 2
GlaxoSmithKline, LLC. $23.65 1
AMAG Pharmaceuticals, Inc. $20.42 1
SANOFI-AVENTIS U.S. LLC $19.60 1
EMD Serono, Inc. $15.33 1
Gilead Sciences, Inc. $13.35 1
Taiho Oncology, Inc. $13.12 1
Advanced Accelerator Applications $12.15 1
Array BioPharma Inc. $11.83 1
Secura Bio, Inc. $9.00 1

Page 5 of 9; records 201–250 of 412 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SRIDHAR BEERAM

NPI 1275626970 · CMS profile ID 193459

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 9; records 201–250 of 412 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275626970?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SRIDHAR BEERAM, NPI 1275626970, CMS profile ID 193459. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 9; records 201–250 of 412 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275626970?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SRIDHAR BEERAM, NPI 1275626970, CMS profile ID 193459. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 9; records 201–250 of 412 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275626970?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SRIDHAR BEERAM, NPI 1275626970, CMS profile ID 193459, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 9; records 201–250 of 412 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1275626970?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

412 matching records · $19,307.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 412 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 412.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $8.5506/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651400877 CMS
Lilly USA, LLC $10.6306/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658170441 CMS
Merck Sharp & Dohme Corporation $12.0506/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695629211 CMS
AstraZeneca Pharmaceuticals LP $78.7006/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685381925 CMS
Janssen Biotech, Inc. $21.0406/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658325343 CMS
Novartis Pharmaceuticals Corporation $14.2206/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659162522 CMS
Exelixis Inc. $10.4206/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686552765 CMS
Janssen Biotech, Inc. $13.3506/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658325339 CMS
AstraZeneca Pharmaceuticals LP $18.8806/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685372399 CMS
GENZYME CORPORATION $9.1006/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694042945 CMS
Incyte Corporation $15.8306/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666258581 CMS
Merck Sharp & Dohme Corporation $11.9706/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695584895 CMS
AbbVie, Inc. $18.4606/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647803711 CMS
Novartis Pharmaceuticals Corporation $12.1906/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659162577 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.4606/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696702805 CMS
E.R. Squibb & Sons, L.L.C. $7.3906/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651400875 CMS
Genentech USA, Inc. $13.8006/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681235987 CMS
Incyte Corporation $6.5506/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666258569 CMS
GENZYME CORPORATION $17.9906/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694307127 CMS
Lilly USA, LLC $5.2206/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658157037 CMS
Lilly USA, LLC $1.8206/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658163647 CMS
Lilly USA, LLC $1.8206/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658173421 CMS
GENZYME CORPORATION $8.5806/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694072911 CMS
Genentech USA, Inc. $12.1506/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681151403 CMS
Amgen Inc. $2.7006/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663058469 CMS
PFIZER INC. $9.9306/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672192165 CMS
Regeneron Healthcare Solutions, Inc. $20.4406/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673339629 CMS
PFIZER INC. $9.5406/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672166725 CMS
AstraZeneca Pharmaceuticals LP $15.7306/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685977119 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.5506/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697400371 CMS
E.R. Squibb & Sons, L.L.C. $6.4206/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651400869 CMS
Merck Sharp & Dohme Corporation $5.7406/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695597813 CMS
Novartis Pharmaceuticals Corporation $5.4205/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659162517 CMS
Puma Biotechnology, Inc. $11.8305/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706017105 CMS
Genentech USA, Inc. $9.0305/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681205087 CMS
Lilly USA, LLC $10.7605/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658170439 CMS
Rigel Pharmaceuticals, Inc. $2.0805/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698992419 CMS
Janssen Biotech, Inc. $14.8605/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658325335 CMS
PFIZER INC. $2,525.0005/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673823043 CMS
Teva Pharmaceuticals USA, Inc. $12.1705/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697711859 CMS
Amgen Inc. $13.8505/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663058434 CMS
Astellas Pharma US Inc $1.5405/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655462883 CMS
Astellas Pharma US Inc $8.1605/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655462887 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.1205/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628412443 CMS
Genentech USA, Inc. $118.7505/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681222957 CMS
Astellas Pharma US Inc $15.0605/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655462881 CMS
Novartis Pharmaceuticals Corporation $4.8305/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659162489 CMS
GENZYME CORPORATION $7.2205/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694073533 CMS
Ipsen Biopharmaceuticals, Inc $25.8105/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640626061 CMS
Astellas Pharma US Inc $9.6205/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655462877 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $19,307.07 412
PY2020 $4,007.33 69
PY2021 $8,305.45 13
PY2022 $5,941.78 22
PY2023 $1,426.50 18
PY2024 $1,905.24 33
PY2025 $707.81 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $90,261.00 17
PY2023 Principal investigator $176,677.40 11
PY2022 Principal investigator $30,363.00 9
PY2021 Principal investigator $50,730.96 22
PY2020 Principal investigator $23,948.35 11
PY2019 Principal investigator $22,523.85 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175323320
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175325134
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175319441
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175324994
Principal investigator 1 Janssen Research & Development, LLC $17,661.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175322676
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175320305
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175324130
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 10/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175319409
Principal investigator 1 Janssen Research & Development, LLC $20,500.00 10/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175322432
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 10/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175323344
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175325765
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 10/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy No dispute reported 06/30/2026 1175320213
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 09/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175324832
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175323293
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175325473
Principal investigator 1 Janssen Research & Development, LLC $20,500.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175323587
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 06/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer No dispute reported 06/30/2026 1175325619